Treatment of scleroderma or systemic sclerosis is difficult, incomplete, and not curative, as the etiology and pathogenesis of the scleroderma disorders are poorly understood. As there is no cure, treatment is directed at controlling and managing the symptoms. Much can be done to help, and the aims of any treatment are always to relieve symptoms and prevent the condition from progressing – as much as it is possible with this chronic disease. Scleroderma can have many symptoms, and a combination of approaches is often needed to treat and manage the disease effectively.
Orphan Drug Designation Granted to Nintedanib
Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Positive opinion on orphan drug designation
With few approved drugs available in SSc, this approach could significantly improve the treatment options in the future.
New therapies – AIMSPRO
The Food and Drug Administration has at the end of February 2014 granted Orphan Drug designation to the therapy AIMSPRO, for systemic sclerosis.
New treatment investigated for SSc
Systemic sclerosis (SSc) is a rapidly progressing systemic form of scleroderma for which there are currently no approved treatments
FESCA, Federation of European Scleroderma Associations aisbl, encourages and undertake surveys, research projects and clinical trials related to the systemic sclerosis disease, and the publication of the results of any such research.
FESCA is always looking for better therapies. This is why we are partners with many different pharma companies. Pay our Scleroderma projects section a visit, and learn more about scleroderma research projects we're involved in.